InVision Medical Technology Corporation (“InVision”) has entered into a collaboration agreement with Alexion, AstraZeneca Rare Disease (“Alexion”) to develop an artificial intelligence (AI) algorithm for analysis of routine echocardiograms, with the aim to accelerate early detection of patients with amyloidosis with cardiac involvement.
Cardiac amyloidosis is a rare but serious disease characterized by a build-up of amyloid in the heart — without treatment, it can lead to heart failure and death. Unfortunately, cardiac amyloidosis is often misdiagnosed or underdiagnosed, given the overlap of symptoms with other etiologies of heart failure. However, subtle signatures that can be better identified with AI in routine imaging can aid the cardiologist with diagnosis. InVision will work with Alexion to develop an AI algorithm to aid timely diagnosis and to reduce misdiagnosis of different forms of cardiac amyloidosis.
“With transformative new therapeutics in development, early diagnosis of cardiac amyloidosis can drastically decrease burden of disease and improve patient quality of life. AI can improve access to care, allowing for timely, precise, and accurate detection of rare diseases,” said Dr. David Ouyang, Co-Founder, InVision. “Echocardiography is a key early exam in the cardiovascular care delivery pathway. We aspire to prevent misdiagnosis or underdiagnosis of rare diseases, and with AI, we can democratize access to expert care to more patients.”
The InVision team has led the development of numerous state of the art echo AI algorithms, with publications in Nature, Nature Medicine, and JAMA Cardiology. These algorithms have been validated in clinical settings, including a first of its kind blinded, randomized clinical trial that was published in Nature 2023 and presented as a late breaking clinical trial at the European Society of Cardiology Congress 2022.
